Australia markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.86-0.68 (-1.56%)
At close: 04:00PM EST
42.86 0.00 (0.00%)
After hours: 05:41PM EST

Apellis Pharmaceuticals, Inc.

100 Fifth Avenue
Waltham, MA 02451
United States
617 977 5700

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 486

Key executives

NameTitlePayExercisedYear born
Dr. Cedric FrancoisCo-Founder, Pres, CEO & Director1.05M7.76M1972
Dr. Pascal Deschatelets Ph.D.Co-Founder & Chief Scientific Officer674.36k9.49M1970
Mr. Alec Machiels J.D., MBACo-Founder & Independent Director67.5kN/A1973
Mr. Timothy E. SullivanChief Financial Officer687.96kN/A1971
Ms. Nur NicholsonChief Technical Operations Officer373.4kN/AN/A
Mr. Adam J. TownsendChief Commercial Officer657.29kN/A1977
Dr. Federico Grossi M.D., Ph.D.Co-Founder & Chief Medical OfficerN/AN/A1974
Mr. James G. Chopas CPAVP, Corp. Controller & Chief Accounting OfficerN/AN/A1966
Ms. Meredith KayaSr. VP, Investor Relations & Strategic Fin.N/AN/AN/A
Mr. David O. WatsonGen. CounselN/AN/A1973
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Corporate governance

Apellis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.